Gastrointestinal protection options for direct oral anticoagulants in patients with atrial fibrillation

Natalya M. Vorobyeva , Irina P. Malaya , Alexandra M. Lelkova , Olga N. Tkacheva

For citation:

Abstract

Gastrointestinal bleeding (GIB) associated with the use of direct oral anticoagulants or, as they are also called, new oral anticoagulants (NOAC) is a serious medical problem, the relevance of which will only increase taking into account the constant expansion of the use of anticoagulants. It is especially important that most of the patients receiving NOAC are elderly people with multiple concomitant pathologies, including diseases of the gastrointestinal tract (GI), which makes them classified as patients with a high risk of GIB and, therefore, in need of prescribing gastroprotectors to protect the GI mucosa and prevent GIB. Considering that one of the mechanisms of GIB development during NOAC therapy is associated with their ability to inhibit GI mucosa healing, and the NOAC themselves are factors of aggression for GI and can lead to syndrome of increased epithelial permeability, the use of gastro- and the enteroprotector of rebamipide seems appropriate and probably pathogenetically justified. The randomized REGATA trial initiated at the Russian Gerontological Research and Clinical Center will provide additional information on the use of rebamipide in patients with atrial fibrillation receiving various NOAC.

Key words: direct oral anticoagulants, gastrointestinal tract, gastrointestinal bleeding, syndrome of increased epithelial permeability, rebamipide, protection.

References

1. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy
and safety of new oral anticoagulants with warfarin in patients with
atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;
383: 955–62. DOI: 10.1016/S0140-6736(13)62343-0
2. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review
and meta-analysis. Gastroenterology 2013; 145 (1): 105–112.e15.
DOI: 10.1053/j.gastro.2013.02.041
3. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:
1139–51. DOI: 10.1056/NEJMoa0905561
4. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin
in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91.
DOI: 10.1056/NEJMoa1009638
5. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin
in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–
104. DOI: 10.1056/NEJMoa1310907
6. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11):
981–92. DOI: 10.1056/NEJMoa1107039
7. Kolb JM, Flack KF, Chatterjee-Murphy P et al. Locations and Mucosal
Lesions Responsible for Major Gastrointestinal Bleeding in Patients
on Warfarin or Dabigatran. Dig Dis Sci 2018; 63 (7): 1878–89. DOI:
10.1007/s10620-018-5007-6
8. Sun DC, Shay H. Basal gastric secretion in duodenal ulcer patients: its
consideration in evaluation of gastric secretory inhibitants or stimulants. J Appl Physiol 1957; 11 (2): 148–54. DOI: 10.1152/jappl.1957.11.2.148
9. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная
патология в клинической практике. Алгоритмы диагностики и
лечения. Кардиоваскулярная терапия и профилактика. 2019; 18
(1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66
[Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in
clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019; 18 (1): 5–66. DOI:
10.15829/1728-8800-2019-1-5-66 (in Russian).]
10. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021; 20 (1): 2758. DOI:
10.15829/1728-8800-2021-2758
[Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary
national Consensus. Cardiovascular Therapy and Prevention. 2021;
20 (1): 2758. DOI: 10.15829/1728-8800-2021-2758 (in Russian).]
11. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel
oral anticoagulants: Risk, prevention and management. World J
Gastroenterol 2017; 23 (11): 1954–63. DOI: 10.3748/wjg.v23.i11.1954
12. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and
nonsteroidal anti-inflammatory drugs in the general U.S. population.
Pharmacoepidemiol Drug Saf 2014; 23 (1): 43–50. DOI:
10.1002/pds.3463
13. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal
antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013; 16 (5): 821–47.
DOI: 10.18433/J3VW2F
14. Shimamoto T, Yamamichi N, Kodashima S et al. No association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis,
and non-erosive reflux disease: a cross-sectional study of 8,013
healthy subjects in Japan. PLoS One 2013; 8 (6): e65996. DOI:
10.1371/journal.pone.0065996
15. Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding
with the new oral anticoagulants – defining the issues and the management strategies. Thromb Haemost 2013; 110 (2): 205–12. DOI:
10.1160/TH13-02-0150
16. Консенсус экспертов по снижению риска желудочно-кишечных
кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021; 10: 23–41. DOI: 10.18565/therapy.2021.
10.23–41
[Experts consensus on reducing the risk of gastrointestinal bleeding in
patients receiving oral anticoagulants. Therapy. 2021; 10: 23–41.
DOI: 10.18565/therapy.2021.10.23–41 (in Russian).]
17. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term
Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017; 152 (4): 706–15. DOI: 10.1053/j.gastro.2017.01.031
18. Xie Y, Bowe B, Li T et al. Risk of death among users of Proton Pump
Inhibitors: a longitudinal observational cohort study of United States
veterans. BMJ Open 2017; 7 (6): e015735. DOI: 10.1136/bmjopen2016-015735
19. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular
Events: A Systematic Review. Heart Lung Circ 2018; 27 (4): 443–50.
DOI: 10.1016/j.hlc.2017.10.020
20. Maggio M, Corsonello A, Ceda GP et al. Proton pump inhibitors and
risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013; 173 (7):
518–23. DOI: 10.1001/jamainternmed.2013.2851
21. Румянцева Д.Е., Трухманов А.С., Кудрявцева А.В., Ивашкин В.Т.
Влияние кислотосупрессии на микробиоту желудочно-кишечного тракта. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28 (1): 78–88. DOI: 10.22416/1382-
4376-2018-28-1-78-88
[Rumyantseva D.Y., Trukhmanov A.S., Kudryavtseva A.V., Ivashkin
V.T. Effect of antisecretory treatment on gastrointestinal microbiota.
Russian Journal of Gastroenterology, Hepatology, Coloproctology.
2018; 28 (1): 78–88. DOI: 10.22416/1382-4376-2018-28-1-78-88 (in
Russian).]
22. Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin
Gastroenterol 2018; 34 (3): 175–82. DOI: 10.1097/MOG. 00000000
00000427
23. Washio E, Esaki M, Maehata Y et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug Induced Small Bowel
Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol 2016; 14 (6): 809–815.e1. DOI: 10.1016/j.cgh.2015.10.022
Обзор / Review
24. Chen WC, Lin KH, Huang YT et al. The risk of lower gastrointestinal
bleeding in low-dose aspirin users. Aliment Pharmacol Ther 2017; 45
(12): 1542–50. DOI: 10.1111/apt.14079
25. Chan EW, Lau WC, Leung WK et al. Prevention of Dabigatran-Related
Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology 2015; 149 (3): 586–595.e3. DOI:
10.1053/j.gastro.2015.05.002
26. Maruyama K, Yamamoto T, Aoyagi H et al. Difference between the
Upper and the Lower Gastrointestinal Bleeding in Patients Taking
Nonvitamin K Oral Anticoagulants. Biomed Res Int 2018; 2018:
7123607. DOI: 10.1155/2018/7123607
27. Youn SH, Lim H, Ju Y et al. Effect of gastroprotective agents on upper gastrointestinal bleeding in patients receiving direct oral anticoagulants. Scand J
Gastroenterol 2018; 53 (12): 1490–5. DOI: 10.1080/00365521.2018.1541478
28. Yamashita T, Watanabe E, Ikeda T et al. Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with
non-valvular atrial fibrillation. J Arrhythm 2014; 30: 478–84. DOI:
10.1016/j.joa.2014.02.011

For citation:Vorobyeva N.M., Malaya I.P., Lelkova A.M., Tkacheva O.N. Gastrointestinal protection options for direct oral anticoagulants in patients with atrial fibrillation. Clinical review for general practice. 2022; 3: 43–49. DOI: 10.47407/kr2022.3.3.00133

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice